Highlights

  • Racura Oncology (ASX:RAC) shares were trading at A$2.20 on 13 July 2026, up 0.46%.
  • The company was formerly Race Oncology; the name change to Racura Oncology took effect on the ASX from 10 December 2025, with the ticker RAC unchanged.
  • Its lead asset is RC220, a proprietary formulation of (E,E)-bisantrene, described as silencing the MYC cancer driver via G-quadruplex binding.
  • RC220 is being advanced across a planned Phase 3 program in acute myeloid leukaemia and Phase 1 programs in EGFR-mutant lung cancer (HARNESS-1) and with doxorubicin (CPACS).
  • Racura reported cash reserves of about A$19.38 million at 31 March 2026 and raised further capital during 2026, but as a clinical-stage biotech it carries funding and dilution risk.

A quiet rise for a renamed ASX oncology developer

Racura Oncology Limited (ASX:RAC) edged higher on 13 July 2026, rising 0.46% to A$2.20, at the time of writing, and giving the company a market capitalisation of approximately A$429.39 million. That places it in the mid-tier of the ASX biotechnology sector, a clinical-stage oncology developer sizeable among Australian cancer-therapy hopefuls.

The modest gain is notable mainly for the story behind the ticker: the company trading as RAC is the former Race Oncology, which adopted the Racura Oncology name on the ASX from 10 December 2025. That recent rebrand is the first fact to verify. What follows reviews what is verifiable about Racura Oncology as of 13 July 2026, separating fact from analysis. It is not financial or medical advice.

What happened to Racura Oncology shares?

On the 13 July 2026 snapshot, Racura Oncology (ASX:RAC) traded at A$2.20, up 0.46%. Investors should treat that as a delayed, point-in-time figure; ASX prices are delayed at least 20 minutes and may since have moved. Available data around this period suggested the stock had been volatile, with reference to a high near A$2.70 earlier in the preceding month. A sub-one-percent daily move is well within normal volatility for a clinical-stage biotech and does not, by itself, indicate a shift in fundamentals.

Was there a verified catalyst?

Based on the searches conducted for this article, no company announcement dated 13 July 2026 was identified that clearly explains the 0.46% gain, so the move is best read as routine trading. What can be verified is a sequence of developments in the preceding months that keep Racura in view: the December 2025 name change; dosing of the first HARNESS-1 patient in late June 2026; a positive independent safety review for CPACS in May 2026; and MYC-silencing data presented at a major cancer conference in April 2026. The honest reading is that the day's gain does not appear tied to a specific verified catalyst.

What does Racura Oncology (ASX:RAC) do?

Racura Oncology is a clinical-stage biopharmaceutical company developing cancer therapies built around a single lead molecule. Its stated mission centres on "silencing" cancer, a reference to the way its drug is described as suppressing a key cancer-driving gene. Following its rebrand from Race Oncology, it operates under the Racura Oncology name while retaining the RAC ticker.

Its identity rests almost entirely on (E,E)-bisantrene, also referred to as RCDS1, and its proprietary formulation RC220. Bisantrene is a small-molecule anticancer agent studied decades ago; Racura has worked to characterise its mechanism, protect it with new intellectual property, and develop an improved formulation. As a clinical-stage developer, Racura has no approved product or product revenue, a defining feature of its risk profile.

Key products, technologies and clinical programs

RC220, the proprietary (E,E)-bisantrene formulation, is the centre of Racura's pipeline. The company describes the molecule as functioning primarily through binding to G-quadruplex (G4) DNA and RNA structures, thereby silencing expression of the MYC oncogene, a master regulator implicated in a large share of cancers, with additional activity referenced against enzymes such as topoisomerase II. This mechanism was highlighted in data presented at the AACR 2026 conference and in work with academic collaborators including Purdue University.

Clinically, RC220 is advanced across several fronts. The most advanced is a Phase 3 program in relapsed or refractory acute myeloid leukaemia (AML), expected to open for recruitment later in 2026. Two Phase 1 programs are recruiting: HARNESS-1, a Phase 1a/b study of RC220 combined with osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer, which dosed its first patient in late June 2026; and CPACS, a Phase 1 study of RC220 as monotherapy and combined with the anthracycline doxorubicin. Phase 1 trials primarily assess safety, dosing and early signals, and are distinct from the pivotal evidence required for approval.

Clinical-development position

Racura's development stage is mixed and should be read precisely. The AML program is described as Phase 3, the most advanced stage, but at the snapshot date it was a planned trial expected to open for recruitment later in 2026 rather than a completed study. HARNESS-1 and CPACS sit at Phase 1, the earliest stage of human testing. Bisantrene's historical record provides context but not a substitute for RC220's own results: the company has referenced older Phase 3 data in which bisantrene showed survival efficacy comparable to doxorubicin with lower cardiac damage, but such data relate to earlier formulations and do not guarantee outcomes for RC220. CPACS drew a positive independent Safety Review Committee recommendation in May 2026, and HARNESS-1 reported no adverse events in its first dosed patient, but these are early safety observations rather than efficacy conclusions.

Regulatory and commercial pathway

As a clinical-stage company, Racura Oncology has no approved product and therefore no current commercialisation. Its regulatory pathway depends on generating positive, prespecified clinical data and advancing through the required trial phases before any submission to agencies such as the TGA, FDA or EMA. A submission, if reached, would be a filing rather than an approval, with no assurance any program will reach that stage. Commercially, the appeal rests on the breadth of potential indications for a MYC-silencing agent and on the intellectual property filed around (E,E)-bisantrene, but realising value would require successful trials, regulatory clearance and either partnering or building commercial capability.

Latest financial position

Racura reported cash reserves of about A$19.38 million as at 31 March 2026, which it characterised as providing several quarters of funding at then-current burn rates. All figures are in Australian dollars for the stated period. During 2026 the company undertook further capital raising, including a placement to a specialist institutional investor and share issuance under option underwriting. Reporting indicated it had raised more than A$34 million from shareholders over roughly two prior years.

For a pre-revenue clinical-stage biotech, cash runway is central. Racura's funding supports its pipeline, but running a Phase 3 AML program alongside Phase 1 studies is capital-intensive, and further raisings could be required, which may dilute existing shareholders. Investors typically monitor quarterly cash-flow (4C) reports for burn rate and runway; the figures above are point-in-time.

Market opportunity

The market opportunity Racura is pursuing is defined by MYC biology. Because MYC is dysregulated in a large proportion of human cancers, a therapy that reliably silences it could, in principle, address a broad addressable market spanning haematological cancers such as AML and solid tumours such as lung cancer, both areas of significant unmet need. This breadth is the core of the bull case, but it is potential rather than proven: each program must succeed on its own clinical merits, and competition in oncology is intense.

Recent official announcements

Verifiable recent developments include the change of company name to Racura Oncology, effective on the ASX from 10 December 2025; presentation of MYC-silencing bisantrene data at AACR 2026 in April 2026; a positive independent Safety Review Committee recommendation for the CPACS study in May 2026; dosing of the first patient in the HARNESS-1 lung-cancer trial in late June 2026; ethics approval to expand HARNESS-1 across additional Australian sites; and capital-raising activity during 2026. Investors should consult Racura Oncology's ASX announcements platform for the primary record.

Potential positive considerations

Several factors may be viewed constructively. Racura has a differentiated scientific narrative, positioning RC220 as a MYC-silencing agent with a defined G-quadruplex mechanism supported by conference data. It has near-term clinical momentum, with HARNESS-1 dosing under way, a positive CPACS safety review, and a Phase 3 AML program slated to open recruitment. Its lead molecule carries a historical clinical record and new intellectual property, and it reported a strengthened cash position during 2026. These are potential positives, not assurances of success.

Main risks and uncertainties

The risks are substantial and typical of clinical-stage oncology. Clinical risk is paramount: early safety signals and historical bisantrene data do not guarantee that RC220 will succeed in modern Phase 1 or Phase 3 trials, and many oncology candidates fail. Regulatory risk follows, as no program has an approval. Funding and dilution risk is real, since the company is pre-revenue, cash-consuming and may need further capital. Concentration risk is high because the entire pipeline rests on a single molecule. Competition, trial-timing slippage and general biotechnology investment risks also apply.

What investors may watch next

The clearest signposts for Racura Oncology (ASX:RAC) are the opening of recruitment in the Phase 3 AML program later in 2026, progress and early data from HARNESS-1, continued safety and dosing updates from CPACS, and quarterly cash-flow reports for burn rate and runway. Investors may also monitor partnering discussions, intellectual-property milestones and capital-raising activity. Each is subject to outcomes that cannot be predicted with certainty.

A balanced view on Racura Oncology (ASX:RAC)

Racura Oncology (ASX:RAC) presents as a scientifically distinctive, clinical-stage ASX oncology developer whose entire thesis rests on RC220 and the MYC-silencing mechanism of (E,E)-bisantrene. The 0.46% rise to A$2.20 on 13 July 2026 was modest and did not appear tied to a specific verified catalyst, but the company remains in focus following its December 2025 rebrand from Race Oncology and a run of clinical milestones through 2026. The potential spans multiple high-need cancer indications, yet it is unproven: every program remains in development, the balance sheet must fund capital-intensive trials, and single-asset concentration amplifies the stakes. Whether RAC is "one to watch" depends on clinical results that are not assured. This article is informational.